Scarica l'app Stockscreener
945.34
1.46%
-13.57
Precedente Chiudi:
$958.91
Aprire:
$957.215
Volume 24 ore:
112.62K
Relative Volume:
0.38
Capitalizzazione di mercato:
$59.12B
Reddito:
$4.16B
Utile/perdita netta:
$1.29B
Rapporto P/E:
48.27
EPS:
19.5837
Flusso di cassa netto:
$734.26M
1 W Prestazione:
-1.80%
1M Prestazione:
-8.13%
6M Prestazione:
+27.15%
1 anno Prestazione:
+23.14%
Intervallo 1D:
$943.31
$972.38
Intervallo di 1 settimana:
$943.31
$977.01
Portata 52W:
$661.85
$1,072.75
Argen X Se Adr Stock (ARGX) Company Profile
Compare ARGX vs VRTX, MRNA, REGN, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARGX
Argen X Se Adr
|
945.01 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
VRTX
Vertex Pharmaceuticals Inc
|
508.57 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
192.07 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
729.26 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
RVMD
Revolution Medicines Inc
|
209.30 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Argen X Se Adr Stock (ARGX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-10 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2025-12-18 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2025-11-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-09-15 | Ripresa | Truist | Buy |
| 2025-09-11 | Downgrade | Deutsche Bank | Buy → Hold |
| 2025-08-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-07-08 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2025-07-03 | Ripresa | Morgan Stanley | Overweight |
| 2025-05-13 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2025-03-17 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2025-03-12 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2025-01-17 | Downgrade | Deutsche Bank | Hold → Sell |
| 2024-11-12 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2024-11-05 | Aggiornamento | Scotiabank | Sector Perform → Sector Outperform |
| 2024-11-01 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-11-01 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2024-10-10 | Ripresa | Raymond James | Strong Buy |
| 2024-10-04 | Downgrade | Deutsche Bank | Buy → Hold |
| 2024-08-06 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2024-07-25 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-07-23 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2023-12-20 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-12-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-07-31 | Iniziato | Scotiabank | Sector Perform |
| 2023-07-24 | Downgrade | UBS | Buy → Neutral |
| 2023-07-17 | Ripresa | Evercore ISI | Outperform |
| 2023-06-15 | Iniziato | Societe Generale | Sell |
| 2023-05-31 | Iniziato | UBS | Buy |
| 2023-04-25 | Iniziato | Citigroup | Buy |
| 2023-03-14 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-12-07 | Iniziato | William Blair | Outperform |
| 2022-10-12 | Iniziato | Oppenheimer | Perform |
| 2022-07-29 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2022-06-28 | Ripresa | Stifel | Buy |
| 2022-05-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-12-08 | Iniziato | Wells Fargo | Overweight |
| 2021-11-29 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-10-29 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-10-28 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2021-10-07 | Iniziato | Jefferies | Buy |
| 2021-09-23 | Aggiornamento | Redburn | Neutral → Buy |
| 2021-09-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-23 | Iniziato | Deutsche Bank | Hold |
| 2021-07-19 | Ripresa | Wolfe Research | Outperform |
| 2021-06-18 | Iniziato | UBS | Buy |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-05-10 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2021-04-23 | Iniziato | Redburn | Neutral |
| 2021-03-05 | Reiterato | H.C. Wainwright | Neutral |
| 2021-02-02 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-01-04 | Downgrade | Guggenheim | Buy → Neutral |
| 2020-08-25 | Iniziato | Raymond James | Outperform |
| 2020-08-19 | Downgrade | Evercore ISI | Outperform → In-line |
| 2020-07-29 | Iniziato | H.C. Wainwright | Neutral |
| 2020-02-10 | Iniziato | BofA/Merrill | Buy |
| 2019-11-05 | Iniziato | Credit Suisse | Neutral |
| 2019-10-31 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2019-10-22 | Iniziato | JP Morgan | Overweight |
| 2019-09-27 | Iniziato | Wells Fargo | Market Perform |
| 2019-09-16 | Ripresa | Cowen | Outperform |
| 2019-06-28 | Iniziato | Robert W. Baird | Outperform |
| 2019-01-18 | Ripresa | SunTrust | Buy |
| 2019-01-04 | Iniziato | Morgan Stanley | Overweight |
| 2018-12-17 | Iniziato | Goldman | Buy |
| 2018-12-14 | Iniziato | Wolfe Research | Outperform |
| 2018-06-29 | Iniziato | Nomura | Buy |
| 2018-04-09 | Iniziato | SunTrust | Buy |
| 2018-01-29 | Reiterato | JMP Securities | Mkt Outperform |
Mostra tutto
Argen X Se Adr Borsa (ARGX) Ultime notizie
argenx SE (ARGX) Stock Price, News, Quote & History - Yahoo Finance
argenx SE (ARGX) stock price, news, quote and history - Yahoo Finance Singapore
US markets mixed as NY Empire State manufacturing index surges in August - scanx.trade
argenx appoints two non-executive directors to board - Investing.com
argenx at Morgan Stanley conference: broadening beyond vyvgart By Investing.com - Investing.com Australia
argenx at Morgan Stanley conference: broadening beyond vyvgart - Investing.com
argenx at wells fargo healthcare conference: broadening beyond vyvgart By Investing.com - Investing.com Australia
argenx at wells fargo healthcare conference: broadening beyond vyvgart - investing.com
Argenx Se Stock Price Forecast. Should You Buy ARGX? - StockInvest.us
argenx SEADR Key Financial Ratios – Valuation, Profitability & More - Value Research
Janus Henderson Global Life Sciences Diversified ADR Managed Account Q2 2026 Commentary - Seeking Alpha
argenx to Present at Upcoming Investor Conferences - Barchart.com
Resilient Argenx stock holds near record highs after Forte Biosciences acquisition - ad-hoc-news.de
Resilient Argenx stock touches fresh all-time high after Forte Biosciences deal - ad-hoc-news.de
Argenx stock hits all-time high at 1059.86 USD By Investing.com - Investing.com South Africa
argenx Completes Acquisition of Forte Biosciences, Inc. - Barchart.com
Forte Biosciences Director David W. Gryska Sells Entire Stake Amid Merger with argenx BV - Kalkine Media
Why is Argen-X stock climbing today? By Investing.com - Investing.com UK
UBS upgrades argenx stock rating on Vyvgart sales outlook By Investing.com - Investing.com India
UBS Just Upgraded Argenx Stock. Here's Why. - Yahoo Finance
Analysts Are Bullish on Top Healthcare Stocks: Enliven Therapeutics (ELVN), Argenx Se (ARGX) - The Globe and Mail
Deutsche Bank downgrades argenx stock to Hold on valuation By Investing.com - Investing.com Nigeria
Deutsche Bank downgrades argenx stock to Hold on valuation - Investing.com
ETFs Investing in argenx SE Sponsored ADR Stocks - TradingView
Resilient Argenx stock climbs after positive myositis data and fresh analyst targets - Ad-hoc-news.de
RBC Capital raises argenx stock price target on myositis data - Investing.com
Strong Argenx stock extends rally after Vyvgart trial win and analyst target hikes. - Ad-hoc-news.de
Gold Gains 1%; NY Empire State Manufacturing Index Rises In August - Sahm
Citizens raises argenx stock price target to $1,200 on trial results - Investing.com
Oppenheimer Adjusts Price Target on argenx to $1,100 From $1,037, Maintains Outperform Rating - Yahoo Finance
Argenx's Positive Vyvgart Data in Autoimmune Indication Supports Growth and FB102 Broadens Portfolio - morningstar.com
Resilient Argenx stock jumps after positive Vyvgart Phase 3 data - Ad-hoc-news.de
TD Cowen raises argenx stock price target to $1,353 on myositis outlook - Investing.com Australia
ARGX Stock Price, Quote & Chart - ChartMill
European ADRs Started The Week Slightly Higher In US Trading - Finimize
There are notable gap-ups and gap-downs in today's session. - ChartMill
H World Group Posts Upbeat Q2 Results, Joins Almonty Industries, Diana Shipping And Other Big Stocks Movi - Benzinga
Argx stock hits all-time high at 954.5 USD By Investing.com - Investing.com Canada
argenx reports positive Phase 3 ALKIVIA results - grafa.com
Zai Lab, argenx report positive phase 3 data for myositis drug - Investing.com India
Why is Argen-X stock surging today? - Investing.com
Why is Argen-X stock surging today? By Investing.com - Investing.com India
Argenx shares jump after positive Phase 3 results in autoimmune myositis trial - Investing.com South Africa
Argx stock hits all-time high at 954.5 USD - Investing.com
T. Rowe Price (ARGX) discloses 2.68M argenx SE ADRs with 4.3% ownership - Stock Titan
Forte Biosciences earnings on deck as $2.2 billion argenx deal nears - Investing.com
Argenx stock holds near recent highs as half year 2026 update and Forte deal shape outlook - AD HOC NEWS
Weekly Recap: Cash tender offer for Forte and EGM on director appointments - TradingView
Galapagos ADR Representing Ord Shs (LKFT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
argenx launches tender offer for Forte Biosciences at $77 per share - Investing.com
argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc. - Barchart.com
Argen X Se Adr Azioni (ARGX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.03%
3.80%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):